Gambro announced an agreement to acquire CHF Solutions, Inc., a medical device company that manufactures and distributes ultrafiltration devices to treat fluid overload.
CHF's leading product is the proprietary Aquadex FlexFlow system, a mechanical pump and filter to treat fluid overload. The Aquadex FlexFlow system uses a simplified approach to ultrafiltration for the removal of salt and water in patients with fluid overload. Compared to renal replacement devices used for ultrafiltration, the Aquadex FlexFlow system is smaller and more portable. The system consists of a console, disposable circuit and disposable venous catheter that can be placed in either a central or peripheral location. Ultrafiltration with the system can be provided to patients in multiple treatment venues.
"Gambro and CHF share a common dedication to pioneering life-saving therapies for patients," said Nick Mendez, President of the Gambro Acute Business Unit. "This acquisition will enable Gambro to accelerate the adoption of ultrafiltration for fluid overload, thereby expanding our product offerings and providing a broader spectrum of care to patients. CHF brings a proven therapy, superior clinical results and established relationships with physicians."
"We are pleased to become part of a company that shares our commitment to improving patient outcomes through innovative technologies," said David Springer, President and CEO of CHF Solutions, Inc. "We look forward, with Gambro's support, to continuing to expand access to ultrafiltration therapy for many more patients."
About Ultrafiltration
Ultrafiltration is an extracorporeal treatment in which water, salt, and other blood constituents are removed by a filter. Ultrafiltration was first prescribed as a therapy for diuretic resistant patients more than 35 years ago and numerous subsequent studies have demonstrated clinical benefits in such patients.
